Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DRUG On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDRUGBright Minds Biosciences$86.28+3.3%$81.11$23.17▼$123.75$812.64M-5.35223,569 shs199,103 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDRUGBright Minds Biosciences+3.33%+15.75%-3.23%-4.13%+197.41%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDRUGBright Minds Biosciences$86.28+3.3%$81.11$23.17▼$123.75$812.64M-5.35223,569 shs199,103 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDRUGBright Minds Biosciences+3.33%+15.75%-3.23%-4.13%+197.41%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDRUGBright Minds Biosciences 2.86Moderate Buy$143.8366.71% UpsideCurrent Analyst Ratings BreakdownLatest DRUG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2026DRUGBright Minds Biosciences Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$190.00 ➝ $220.004/13/2026DRUGBright Minds Biosciences Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$145.003/30/2026DRUGBright Minds Biosciences BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$147.003/4/2026DRUGBright Minds Biosciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$115.00 ➝ $145.00(Data available from 5/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDRUGBright Minds BiosciencesN/AN/AN/AN/A$23.11 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDRUGBright Minds Biosciences-$8.74M-$2.44N/AN/AN/AN/A-20.58%-20.25%8/13/2026 (Estimated)Latest DRUG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2026Q2 2026DRUGBright Minds Biosciences-$0.8633-$0.80+$0.0633-$0.80N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthDRUGBright Minds BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDRUGBright Minds BiosciencesN/A81.4781.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDRUGBright Minds Biosciences40.52%Insider OwnershipCompanyInsider OwnershipDRUGBright Minds Biosciences42.66%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDRUGBright Minds BiosciencesN/A9.73 million5.58 millionNot OptionableDRUG HeadlinesRecent News About These CompaniesBright Minds Biosciences to Present at Jefferies Global Healthcare ConferenceMay 26 at 7:18 PM | globenewswire.comWhy a $5 Million New Position Signals Confidence in This Epilepsy Drug PipelineMay 21, 2026 | finance.yahoo.comBright Minds Biosciences Inc. (NASDAQ:DRUG) Receives Average Recommendation of "Moderate Buy" from BrokeragesMay 17, 2026 | americanbankingnews.comBright Minds Biosciences (DRUG) to Release Earnings on FridayMay 8, 2026 | marketbeat.comBright Minds Biosciences (NASDAQ:DRUG) Major Shareholder Cormorant Asset Management, Lp Sells 109,331 SharesMay 1, 2026 | insidertrades.comInsider Selling: Bright Minds Biosciences (NASDAQ:DRUG) Major Shareholder Sells 109,331 Shares of StockApril 30, 2026 | marketbeat.comJefferies initiates coverage of Bright Minds Biosciences (DRUG) with buy recommendationApril 14, 2026 | msn.comWhat Is the Probability of Success for Bright Minds Biosciences Inc (DRUG)’s Lead Drug Candidate?March 25, 2026 | insidermonkey.comBright Minds Biosciences to Present at Upcoming ConferencesFebruary 25, 2026 | globenewswire.comWhy Bright Minds Biosciences Inc.’s (DRUG) Stock Is Down 7.62%February 24, 2026 | aaii.comABaird Lowers Bright Minds Biosciences Inc. (DRUG) Price Target to $126, Maintains Outperform Rating Ahead of Upcoming TrialsFebruary 20, 2026 | finance.yahoo.comBaird Lowers Bright Minds Biosciences Inc. (DRUG) Price Target to $126, Maintains Outperform Rating Ahead of Upcoming TrialsFebruary 18, 2026 | insidermonkey.comBTIG Sticks to Its Buy Rating for Bright Minds Biosciences (DRUG)February 15, 2026 | theglobeandmail.comBright Minds Biosciences Files Q1 FY2026 Financials Showing Strong Cash, Higher R&D LossFebruary 13, 2026 | tipranks.comBright Minds Biosciences Unveils Strong Phase 2 Data for BMB-101 in Drug-Resistant Seizure DisordersJanuary 16, 2026 | theglobeandmail.comBright Minds Biosciences Announces Closing of US$175 Million Public OfferingJanuary 9, 2026 | globenewswire.comBright Minds Biosciences Announces Pricing of Upsized US$175 Million Public Offering of Common StockJanuary 7, 2026 | globenewswire.comBright Minds Biosciences Ends Equity Distribution Deal With Piper Sandler and CantorJanuary 7, 2026 | tipranks.comBright Minds Biosciences: Positive BREAKTHROUGH Study Data Warrants 'Strong Buy' RatingJanuary 7, 2026 | seekingalpha.comBright Minds Biosciences Launches US$100 Million Public Offering to Fund CNS Drug PipelineJanuary 7, 2026 | tipranks.comBright Minds announces results from phase 2 BREAKTHROUGH trial of BMB-101January 6, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesLilly's Double-Beat Widens the GLP-1 Gap—And a New Pill Could Make It PermanentBy Nathan Reiff | May 1, 2026These 3 Psychedelic Stocks Activated After Trump's Executive OrderBy Nathan Reiff | April 27, 2026Amazon Takes a Bite Out of Hims: What Its GLP-1 Entrance MeansBy Leo Miller | April 28, 20262 Ways to Play the Big Pharma Patent CliffBy Nathan Reiff | May 15, 2026Mirum Pharma: A Rare Disease Growth Story to WatchBy Chris Markoch | May 20, 2026DRUG Company DescriptionsBright Minds Biosciences NASDAQ:DRUG$86.28 +2.78 (+3.33%) As of 05/26/2026 04:00 PM EasternBright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AutoZone's Pullback Sets Up a Long-Term Buying Opportunity AST SpaceMobile’s June Launch Plan Puts Its 2026 Satellite Goal Back in Focus Powerhouse Williams-Sonoma Heading to Fresh Highs in 2026 Quantum Stocks Just Got a Lifeline—Who Benefits Most? Why BJ’s Wholesale Club Stock Could Be Ready for a Rebound 5 High-Yield Stocks and ETFs to Buy and Hold for the Next Decade Rocket Companies Turns Around, But Mortgage Risk Remains After NVIDIA, Broadcom's Earnings Are Next—Here's What to Watch Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
